SSKNOTCSurgical & Medical Instruments & ApparatusUS GAAP · USD

STRATA Skin Sciences, Inc.

STRATA Skin Sciences, Inc. is a U.S.-based medical technology company focused on dermatology devices and treatment systems. Its portfolio includes excimer laser and lamp platforms used by dermatologists to treat psoriasis, vitiligo, acne, and other skin conditions, with sales and procedures centered in the United States and select international markets.

Liikevaihto30,7milj. USD
−8,5 %v/v
Liikevoitto (EBIT)−4,7milj. USD
+49,2 %v/v
EBIT-marginaali−15,3%
+12,3 %-yks.v/v
Nettotulos−6,3milj. USD
+37,9 %v/v
Vapaa kassavirta−4,3milj. USD
−194,3 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−10010203040milj. USD2020: 23 milj. USD2020: EBIT −4,1 milj. USD20202021: 30 milj. USD2021: EBIT −4,4 milj. USD20212022: 36 milj. USD2022: EBIT −4,6 milj. USD20222023: 33 milj. USD2023: EBIT −8,6 milj. USD20232024: 34 milj. USD2024: EBIT −9,3 milj. USD20242025: 31 milj. USD2025: EBIT −4,7 milj. USD202531−4,7
LiikevaihtoLiikevoitto (EBIT)

Liiketoiminta

Osuus liikevaihdosta
Dermatology recurring procedures72 %

Treatment revenue from XTRAC procedures and TheraClear device placements recognized over usage.

Dermatology procedures equipment28 %

Sales of excimer lasers, lamp systems, accessories, and related equipment to practices.

Asiakkaat

The company sells primarily to dermatology practices and physicians that treat chronic and recurring skin conditions. Its recurring procedures model also serves offices that place STRATA devices and then generate treatment revenue as patients use the systems. Demand is tied to clinical adoption, reimbursement coverage, and the ability of practices to attract patients needing psoriasis, vitiligo, or acne therapy.

Dermatology practices

Buy XTRAC, Pharos, and VTRAC systems to treat psoriasis, vitiligo, and other skin diseases in-office.

Recurring procedure offices

Place STRATA devices and generate treatment revenue as patients return for repeated sessions.

Acne treatment providers

Use TheraClear X for acne-related skin conditions and related patient care workflows.

International dermatology customers

Purchase equipment and procedures outside the U.S. where the company has international exposure.

Strategia

STRATA’s strategy centers on expanding installed base usage, placing devices in dermatology offices, and converting that footprint into recurring treatment revenue. It also emphasizes product development and commercialization across dermatology indications, while managing the economics of device refurbishment and redeployment to support utilization.

Expand recurring procedure utilizationLyhyt aikaväli

Recurring treatments create repeat revenue tied to installed devices and patient flow.

Increase installed base and device placementsKeskipitkä aikaväli

A larger installed base supports future procedure volume and customer retention.

Optimize device lifecycle economicsKeskipitkä aikaväli

Refurbishing and redeploying units can lower capital needs versus building new systems.

Maantiede

Q3/2025

STRATA is headquartered in the United States and its reported recurring procedures activity is concentrated there. The company also notes international customer activity, which can affect collections timing and exposure to trade policy, tariffs, and cross-border supply chain costs. Geography matters because the business depends on U.S. reimbursement dynamics while importing components and serving some customers abroad.

USA75 %
Other countries (US filing)20 %
Middle East2,5 %
Kina1,9 %

Osuus liikevaihdosta, jonka yhtiö raportoi maantieteellisesti.

Riskit

The business is exposed to reimbursement, adoption, and utilization risk because a meaningful share of revenue depends on repeated dermatology procedures. It also faces tariff, import, and supply-chain risk because products and components may be sourced across borders, while accounting estimates such as revenue deferrals, goodwill, and sales tax liabilities can materially affect reported results.

Järjestetty vakavuuden mukaan
Tariffs and trade restrictionsKorkea

Imported products or components may become more expensive and less competitive.

KohdistuuProduct costsPricingDemand
Reimbursement and utilization dependenceKorkea

Recurring procedure revenue depends on insurance coverage and patient treatment volume.

Kohdistuu: XTRAC and related dermatology procedures

Goodwill and intangible impairmentKorkea

Device and reporting-unit values depend on future cash flow assumptions.

Kohdistuu: Dermatology recurring procedures reporting unit

International collection timingKeskitaso

The company noted longer payment cycles from international customers.

Kohdistuu: Accounts receivable and cash conversion

Kirjanpito

Harkinnanvaraiset erät
Revenue recognition for recurring procedures

Revenue is deferred and recognized as treatments are used, affecting quarterly timing.

Vaikutus: Can shift revenue between periods

Deferred revenue on domestic placements

Placed devices generate future treatment revenue that is not recognized immediately.

Vaikutus: Affects reported revenue and contract liabilities

Goodwill impairment

The dermatology recurring procedures reporting unit depends on valuation assumptions.

Vaikutus: Can create non-cash charges if expected cash flows weaken

Sales tax liability estimates

Management disclosed a methodology error that affected accrued expenses and expense recognition.

Vaikutus: Can alter liabilities, operating expense, and goodwill carrying value

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Päivitetty: 24.9.2026

STRATA Skin Sciences, Inc. (OTC) – Surgical & Medical Instruments & Apparat | Analyysi – Clarifo